Chugai Pharmaceutical Co., Ltd.
Other OTCTotal Valuation
Chugai Pharmaceutical Co., Ltd. carries a market capitalization of 78.42B, placing it among publicly traded companies globally. Its enterprise value stands at 8.58T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 78.42B |
| Enterprise Value | 8.58T |
Share Statistics
Chugai Pharmaceutical Co., Ltd. currently has 1.65B shares outstanding.
| Shares Outstanding | 1.65B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Chugai Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 26.48.
| PE Ratio | 26.48 |
| PS Ratio | 8.67 |
| PB Ratio | N/A |
| P/TBV Ratio | 5.43 |
| P/FCF Ratio | 24.14 |
| P/OCF Ratio | 28.74 |
Enterprise Valuation
On an enterprise value basis, Chugai Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 17.65 and an EV/FCF ratio of 22.04. The EV/Sales ratio of 7.92 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.65 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.92 |
| EV / EBITDA | 17.65 |
| EV / EBIT | 17.65 |
| EV / FCF | 22.04 |
Financial Position
Chugai Pharmaceutical Co., Ltd. maintains a current ratio of 5.09, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.09 |
| Quick Ratio | 2.81 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 32,430.47 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 18.25 |
| Return on Invested Capital (ROIC) | 20.80 |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.24 |
Taxes
Over the trailing twelve months, Chugai Pharmaceutical Co., Ltd. has paid 133.82B in income taxes, reflecting an effective tax rate of 27.37.
| Income Tax | 133.82B |
| Effective Tax Rate | 27.37 |
Stock Price Statistics
Chugai Pharmaceutical Co., Ltd.'s stock has declined approximately -5.12246% over the past 52 weeks. The 50-day moving average sits at 52.43, while the 200-day moving average is 51.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | -5.12246% |
| 50-Day Moving Average | 52.43 |
| 200-Day Moving Average | 51.94 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chugai Pharmaceutical Co., Ltd. generated 1.08T in revenue and converted that into 355.04B in net income, yielding earnings per share of 214.30. EBITDA reached 486.46B, while operating income came in at 486.46B.
| Revenue | 1.08T |
| Gross Profit | 753.36B |
| Operating Income | 486.46B |
| Pretax Income | 488.86B |
| Net Income | 355.04B |
| EBITDA | 486.46B |
| EBIT | 486.46B |
| Earnings Per Share (EPS) | 214.30 |
Balance Sheet
| Cash & Cash Equivalents | 815.66B |
| Total Debt | N/A |
| Net Debt | -393.76B |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 1.19T |
Cash Flow
Chugai Pharmaceutical Co., Ltd. produced 327.07B in operating cash flow over the past twelve months. After subtracting -62.36B in capital expenditures, free cash flow totaled 264.71B - equivalent to 159.79 per share.
| Operating Cash Flow | 327.07B |
| Capital Expenditures | -62.36B |
| Free Cash Flow | 264.71B |
| FCF Per Share | 159.79 |
Margins
Chugai Pharmaceutical Co., Ltd. operates with a gross margin of 69.46, reflecting its pricing power and cost economics. The operating margin of 44.85 and net profit margin of 32.74 provide insight into operational efficiency.
| Gross Margin | 69.46 |
| Operating Margin | 44.85 |
| Pretax Margin | 45.07 |
| Profit Margin | 32.74 |
| EBITDA Margin | 44.85 |
Dividends & Yields
The company's payout ratio of 36.97 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 79.25 |
| Dividend Yield | N/A |
| Payout Ratio | 36.97 |
| Shareholder Yield | 1.48 |
| FCF Yield | 4.14 |
Stock Splits
Chugai Pharmaceutical Co., Ltd.'s most recent stock split took place on June 29, 2020 with a 1:3 split ratio.
| Last Split Date | 6/29/2020 |
| Split Ratio | 1:3 |
Scores
Chugai Pharmaceutical Co., Ltd. posts an Altman Z-Score of 20.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 20.30 |